Fennec Pharmaceuticals Inc(FRX-T)
TSX

Today's Change
Real-Time Last Update
Day Low13.50
Day High14.98
Open:13.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
Fennec Announces Results of Annual Meeting
GlobeNewswire
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
GlobeNewswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
GlobeNewswire
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
Baystreet
Stocks in play: Fennec Pharmaceuticals Inc.
GlobeNewswire
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
INK Research
Public market insider net buying at Fennec Pharmaceuticals (FRX)
Company Chart of FRX
GlobeNewswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Baystreet
Stocks in play: Fennec Pharmaceuticals Inc.
GlobeNewswire
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
GlobeNewswire
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
Baystreet
Stocks in play: Fennec Pharmaceuticals Inc.
GlobeNewswire
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
INK Research
Public market insider buying at Fennec Pharmaceuticals (FRX)
Company Chart of FRX

Profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.